Immunomodulation in solid malignant tumors refractory to standard treatment

In patients with malignant solid tumors refractory to irradiation, chemoterapy and treatment with immunomodulatory agents, the supressed immune response to tumor will be removed and replaced by allogeneic mononuclear cells. Tumor response and survival as well as the effect on patients' immune sistem will be evaluated. Specific anti-tumor cellular and humoral responses induced by deblocking the immune system will be amplified by the use of allogeneic dendritic cells in combination with patient tumor cells. For that purpose cyclophosphamid, anti-lymphocyte T polyclonal and monoclonal antibodies will be applied leading to depletion of lymphocytes T, aiming mostly at activated supressor cells. This treatment will be followed by infusion of allogeneic mononuclear cells with or without dendritic cells in combination with tumor cells to additionally remove supressive barriers and to activate patient's immune system. The concept of this approach is similar to desirable induction of graft versus leukemia effect (GvL) in bone-marrow transplantation. 20 patients will be inclouded. Treatment will be in outpatient and inpatient basis. Duration of treatment will be 42 days.